nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Nouscom is a clinical-stage immuno-oncology company specializing in off-the-shelf and personalized cancer immunotherapies using a proprietary viral vector platform.

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for brain disorders, with plans to advance their pipeline programs, including ML-007C-MA, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis, as well as support their other pipeline programs.